The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISHL12 2022 | Updates on the use of brentuximab vedotin in later-stage HL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, briefly shares some updates on the use of brentuximab vedotin for the treatment of later-stage Hodgkin lymphoma (HL), highlighting the recent overall survival (OS) advantage demonstrated in the ECHELON-1 trial (NCT01712490). This interview took place at The 12th International Symposium on Hodgkin Lymphoma (ISHL12), held in Cologne, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding from Seattle Genetics, BMS, Affimed, Regeneron, Takeda, AstraZeneca, Pfizer, ADC Therapeutics to my institution for clinical trials.
